comprehensive -WSS

comprehensive

author：focus 2025-09-30 22:27:49 - browse：95

Vir Biotechnology said Thursday that a long-acting antibody drug designed to protect healthy individuals from influenza A failed to do so in a nearly 3,000-person clinical trial.

Volunteers who received the highest dose of the drug, known as VIR-2482, were only 16% less likely than the placebo group to develop symptomatic influenza A infections, as defined by trial criteria, over a seven-month period. The difference was not statistically significant.

The results are a setback in broader efforts to develop better protective measures against both seasonal and potential pandemic influenza strains. In the short term, Vir and outside experts hoped VIR-2482 could provide additional annual protection for at-risk groups like older adults, as flu vaccines are often only modestly effective.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： How to save PrEP access — and even expand it
Next article： Alexander Hamilton and the argument for universal insurance

WSS

Biden to sign 'historic' executive order on how US military handles sexual assault cases

Stoke drug shows lower activity against childhood epilepsy

Interest rates are at a 22

Public health communication lessons from Covid

Biden jokes that Republicans may impeach him because inflation is starting to cool down

An outrageous hospital charge: I paid $710 for an hour of babysitting

leisure time

comprehensive

entertainment

Activists slam private health insurers over coverage restrictions

The Jan. 6 committee previously recommended Trump be criminally charged. Here's why

Moonlake's readout produced a cash windfall. Risks remain

The Jan. 6 committee previously recommended Trump be criminally charged. Here's why

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Free medical tuition alone isn't enough to close gaps in primary care

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Supreme Court to hear if Covid misinformation is protected speech

23andMe had bad news about my health. I wish a person had delivered it

CDC: Cases of alpha

entertainment

Stoke drug shows lower activity against childhood epilepsy

Supreme Court to hear if Covid misinformation is protected speech

'Hero' Louisville officer shot in head at mass shooting discharged over 3 months later

Biden jokes that Republicans may impeach him because inflation is starting to cool down

Novo Nordisk testing Wegovy against alcohol

'The boss' wants server deleted: New allegations emerge in Trump indictment

hotspot

hotspot

leisure time

entertainment